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Abstract
Background: The NIMA-related kinase 2 (NEK2) is a serine/threonine kinase that is involved in regulation of
centrosome duplication and spindle assembly during mitosis. Dysregulation of these processes causes chromosome
instability and aneuploidy, which are hallmark changes of many solid tumors. However, whether aberrant
expression of NEK2 is associated with outcome of prostate cancer (PCa) patients remains to be determined.
Methods: Expression of NEK2 in human PCa cells and primary PCa tissues was assessed by quantitative RT-PCR.
Expression of NEK2 in human PCa cells was depleted with siRNA. Effects of the depletion on cell proliferation,
survival, and tumorigenicity were assessed both in vitro with cell cultures and in vivo with subcutaneous
implantation of xenografts. In silico analyses of the online Taylor dataset were carried out to determine whether the
expression level of NEK2 correlated with the clinicopathological characteristics of prostate cancer.
Results: Compared with benign human prostatic epithelial cells and tissues, the expression of NEK2 was elevated in
human PCa cells and primary PCa tissues. Depleting NEK2 expression inhibited human PCa cell proliferation in vitro
and xenograft growth in vivo. Expression level of NEK2 in PCa positively correlated with the Gleason score and
pathologic stage of the patient.
Conclusion: The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa
prognosis. Further validation with large sample pool is warrant.
Background
The centrosome is the primary site of microtubule nu-
cleation in cells, which plays a critical role in mitotic
spindle formation and chromosome segregation [1, 2].
Normally, cells enter mitosis with two properly dupli-
cated centrosomes. The process ensures bipolarity and
correct axial positioning of the spindle. However, cancer
cells often exhibit multipolar spindles associating with
abnormal centrosome numbers or architectures [3–5]. A
number of cell cycle-regulated protein kinases located at
the centrosomes have been identified, which are required
for mitotic progression and correct bipolar spindle forma-
tion [6]. Among them is NIMA-related kinase 2 (NEK2)
that has three alternative splice isoforms (NEK2A, NEK2B
and NEK2C). The expression of these three isoforms is
tightly regulated in a cell cycle-dependent manner, sug-
gesting that they may have isoform-specific roles in
mitosis [7, 8].
NEK2 is a constitutive active serine and threonine kin-
ase that phosphorylates multiple proteins involved in
centrosome duplication and cell cycle regulation. It binds
to microtubules and is enriched in the centrosome, where
it contributes to centrosome splitting during the G2/M
phase of the cell cycle [9]. Aberrant NEK2 activities cause
failure in regulating centrosome duplication, resulting an-
euploidy, and, therefore, are oncogenic [10]. Increased
NEK2 expression causes premature splitting of centro-
somes in human cells. Expression of a kinase-dead mu-
tant of NEK2 induces centrosome abnormalities and
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aneuploidy [11, 12]. Similar to other kinases that are
involved in spindle assembly or duplication, overex-
pression of NEK2 has been reported in several neo-
plastic diseases, such as preinvasive and invasive breast
carcinomas [10], lung adenocarcinomas [13], testicular
seminomas [14], and diffuse large B cell lymphomas
[15]. Overexpression of NEK2 in non-transformed
breast epithelial cells induces over duplication of the
centrosome [10]. Increased expression of NEK2 causes
centrosome amplification in breast cancer cells that
express oncogenic K-RAS [16]. Furthermore, NEK2-
dependent phosphorylation is required for kinetochore
localizations of HEC1, a protein essential for faithful
chromosome segregation [17]. In addition, NEK2 is also
involved in regulation of viability and apoptosis. Depletion
of NEK2 sensitizes HeLa cells to apoptosis and induces
alternative splice of SRSF1 target genes [18].
Although a large number of data demonstrate elevated
expression as well as reduced stability of NEK2 in cancer
cells, whether NEK2 upregulation plays a role in PCa is
not clearly. In this study, we investigated expression pat-
terns of NEK2 in tissue microarrays (TMAs) of human
PCa and the effect of NEK2 depletion on cell prolifera-
tion in PCa cells. The data showed strong correlation of
NEK2 expression with the prognostic outcome of PCa
patients. Together, our results indicate that NEK2 has a
promising value for predicting outcome of PCa recur-
rence. Future studies with large sample pools are war-
ranted to determine whether the expression level of
NEK2 can serve as a biomarkers for PCa prognosis,
which still needs prospective validation.
Methods
Patients and tissue samples
The study was approved by the Research Ethics Commit-
tee of Guangzhou First People’s Hospital, Guangzhou
Medical University, China. An informed consent was ob-
tained from all of the patients. All specimens were han-
dled and remained anonymous according to the ethical
and legal standards.
For immunohistochemistry analyses, TMAs with de-
tail clinical information were purchased from Shanghai
Outdo Biotech Co, LTD (Cat#: HPro-Ade180PG-01),
which includes 99 primary PCa tissues and 81 adjacent
non-cancerous prostate tissues from patients without
chemotherapy or radiotherapy before surgery. The
Taylor dataset (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE21032) contains microarray data for
mRNAs from 149 primary PCa tissues and 29 adjacent
noncancerous prostate tissues [19]. The dataset contains
patient survival time and follow-up examination between
from 1 to 175 months with a median of 51 months post-
surgery. The date of prostatectomy was considered as day
1 for the survival analyses. The PSA recurrence was
defined as three successive PSA rises (final value >0.2 ng/
ml), single PSA >0.4 ng/ml, or use of secondary therapy
administered for detectable PSA >0.1 ng/ml, which was
considered as the biochemical recurrence-free endpoint.
The overall survival that was determined from the date of
surgery to the time of the last follow-up or death.
Cell culture, transfection, and treatment
For cell viability assays, human PCa LNCaP cells were
seeded in 96-well plates (2 × 103/well) and cultured for
24, 48, and 72 h. Cells were then incubated with 20 μl
CCK-8 solution (Cat No: C0038, Beyotime, China) for
4 h at 37 °C. The absorbance was measured at the
wavelength of 495 nm with a spectrophotometer. Data
were expressed as mean ± SD of three independent
samples. For RNA interference experiments, cells were
transfected with siRNAs using Lipofectamine RNAi-
MAX (Invitrogen) according to manufacturer’s instruc-
tions and harvested at 24, 48, and 72 h after the
transfection for protein and RNA analyses. Sequences
of NEK2 siRNAs and scrambled siRNA are listed in
Table 1.
Quantitative real-time RT-PCR
Total RNAs were isolated from cells and prostate
tissues using the TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Reverse transcription was carried out using the ReverTra
Ace reagents kit (TOYOBO, Osaka, Japan). Real-time
RT-PCR was carried out with the MiniOpticon real-time
PCR detection system (Bio-Rad, Hercules, CA, USA)
using the SYBR Green master mix (TaKaRa, Otsu, Japan).
The thermal cycling conditions comprised of one cycle at
94 °C for 4 min, 40 cycles at 94 °C for 15 s, 60 °C for 15 s,
and 72 °C for 15 s. All data were analyzed using the
Opticon Monitor software (ver3.1, Bio-Rad). The expres-
sion of NEK2 was calculated as relative expression level to
the GAPDH internal control using the comparative cycle
threshold (CT) method. The primer sequences for NEK2
are GCTTAGGTAGCCCTTTTCATTTACA and GCC
TCAGGTCTATGAACCCAG. The primer sequences for
GAPDH are CATGGGTGTGAACCATGAGAAGT and
ACAGTAGAGGCAGGGATGATGTTCT.






Zeng et al. BMC Urology  (2015) 15:90 Page 2 of 8
Western blotting analysis
Proteins were extracted 48-hours post-transfection for
Western blot analyses. Proteins (40 μg) were frac-
tioned on SDS-PAGE and transferred onto Hybond
nitrocellulose membranes (GE Healthcare). The mem-
branes were blocked with 5 % skim milk in PBS-Tween
20 and probed with anti-NEK2 (bs-5732R, Bioss Co
Ltd., China) or anti-β-actin antibody (sc-47778, Santa
Cruz, USA). The specifically bound antibodies were de-
tected with horse radish peroxidase-conjugated second-
ary antibody and visualized with the SuperSignal West
PICO Chemiluminescent Detection Kit (Pierce Biotech-
nology). β-actin was used as an internal loading
control.
Tumor growth
All nude mice with an average age of 6–8 weeks were
purchased from the Guangdong Medical Laboratory
Animal Center. The NEK2 silenced cells were injected
on the left side flank and the control cells on the right
side flank. Briefly, 2×106 cells were suspended in 0.1 ml
culture medium, and then mixed with Matrigel (BD
Biosciences,NO.356234) at the ratio of 1:1. The injec-
tions were carried out in a sterilized hood. Five mice
per group were used and the experiments were re-
peated three times. The tumor size was measured with
caliper at three time points and the means were
calculated. The tumor tissues were harvested at day 43
after the implantation for histology and biochemistry
analyses.
Immunohistochemistry analysis
The specimens were fixed in 10 % neutral buffered for-
malin and subsequently embedded in paraffin. The
paraffin-embedded tissues were sectioned at 4 μm
thickness and then deparaffinized with xylene and rehy-
drated for subsequence analyses. For immunohisto-
chemistry staining, the sections were subjected to a
brief proteolytic digestion and a peroxidase blocking,
the sections were incubated overnight with the primary
antibody against NEK2 at a dilution of 1:400, at 4 °C.
After washing, the sections were then incubated with
peroxidase labeled polymer and substrate–chromogen
from DAKO EnVision System (Dako Diagnostics,
Switzerland) to detect the specifically bound antibodies
as suggested by the manufacturer. No primary anti-
bodies were used as the negative controls. The sections
were then lightly counterstained with hematoxylin. The
staining was scored by two independent experienced
pathologists, who were blinded to the clinicopathologi-
cal data and clinical outcomes of the patients. The
scores of the two pathologists were compared. Any dis-
crepant scores were trained through re-examining the
staining by both pathologists to achieve a consensus
Fig. 1 NEK2 expression and function in prostate epithelial cell lines. a & b Real-time RT-PCR analyses of NEK2 expression in benign human prostatic
epithelial cells and PCa cells (a) or NEK2-depleted LNCaP cells. c Western blot analysis for NEK2 protein expression in PrEC and siRNA treated LNCaP
cells. d Proliferation analyses of LNCaP cells with or without depletion of NEK2
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score. The number of positive-staining cells in ten rep-
resentative microscopic fields was counted, and the per-
centage of positive cells was calculated. The staining
was subjected to arbitrative categorized to 5 groups
based on the percentage of positive cells for semi-
quantitative analyses as following: 0 (0 %), 1 (1–10 %), 2
(11–50 %), 3 (51–80 %) and 4 (>80 %). The staining
intensity was visually scored and stratified as follows:
0 (negative), 1 (weak), 2 (moderate) and 3 (strong). A
final immunoreactivity scores (IRS) were obtained for
each case by adding the percentage and the intensity
score [20, 21].
Statistical analysis
The statistical analyses was carried out with the SPSS
software (Version 13.0 for Windows, SPSS Inc., IL,
USA) and SAS 9.1 (SAS Institute, Cary, NC, USA). Con-
tinuous variables were expressed as mean ± SD. The
Fig. 2 Depletion of NEK2 by siRNA inhibits the growth of LNCaP subcutaneous xenograft growth in nude mice. a & b Representative images of
LNCaP xenografts. c Tumor growth curves of LNCaP xenografts. d & e Immunostaining of NEK2 in LNCaP xenografts. The figure magnification
is × 200 and × 400, respectively. f Statistical analysis of the NEK2 positive cells in the immunostaining
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Kaplan–Meier method was used for the survival analyses
and a log-rank test was used to analyze the difference of
survival. The chiquest trend test was used for ordinal
data analysis. Differences were considered statistically
significant when P was smaller than 0.05.
Results
Depleting NEK2 expression reduces cell proliferation in
PCa cells
To determine whether human PCa cells had aberrant
NEK2 expression at the mRNA level, quantitative real-
time RT-PCR was performed to assess the expression of
NEK2 in three human PCa and one benign human pros-
tatic epithelial cell lines. As shown in Fig. 1a, expression
of NEK2 was higher in all three PCa cells than in benign
human prostatic epithelial cells at the mRNA level, espe-
cially in LNCaP cell line. Then we chose LNCaP cells for
the further study to determine whether high expression
of NEK2 contributed to cell proliferation, siRNA was
used to deplete the expression of NEK2 in LNCaP cells.
Both real time RT-PCR and Western blot analyses
showed that the expression of NEK2 was reduced at
both mRNA and protein levels (Fig. 1b&c). Cell prolifer-
ation assays demonstrated that LNCaP cells with NEK2
depletion had a lower proliferation rate than the cells
transfected with scramble siRNAs (Fig. 1d). The results
suggest that high expression of NEK2 promotes cell
proliferation.
Depletion of NEK2 expression suppresses tumorigenicity
of LNCaP cells
To determine whether depletion of NEK2 affected the
tumorigenicity of LNCaP cells, the silenced and control
cells were implanted to the flanks of the same mice. The
tumor sizes were measured at day 14, 23, and 36 post
the implantation. It was apparent that tumors derived
from NEK2 silenced cells were smaller than those from
control cells (Fig. 2a, b&c). The tumors were harvested
at day 43 after the implantation for further analyses.
In addition to smaller size, the tumors with NEK2
silenced cells were relatively pale than the tumors
from control cells (Fig. 2b). Immunostaining revealed
that expression of NEK2 protein was reduced compared
with the tumors derived from scramble siRNA transfected
control cells. High magnification images showed
that nuclear and cytosol staining of NEK2 staining
was visible in control cells, but was absent in NEK2 de-
pleted cells (Fig. 2d&e). The percentage of NEK2 positive
Fig. 3 Immunohistochemical staining for NEK2 expression in PCa and adjacent non-cancerous tissues (original magnification × 50). a Benign
prostate tissue. b PCa with a Gleason score <8. c PCa with a Gleason score ≥8. d statistical analyses showing higher immunoreactivity scores in
cancerous tissues than in adjacent non-cancerous tissues. (IRS: Ca = 4.25 ± 1.36 vs Benign = 2.93 ± 1.51, P =0.03). a, b, and c were from TMA sample
NO. A5, J8, and H8, respectively
Zeng et al. BMC Urology  (2015) 15:90 Page 5 of 8
cells was dramatically decreased in NEK2 siRNA group
(Fig. 2f).
The expression level of NEK2 is associated with the
clinicopathological characteristics of PCa and tumor
recurrence time of PCa patients
We then analyzed the expression pattern and localization
of NEK2 in a PCa TMA comprised of 99 PCa and 81
adjacent non-cancerous prostate tissues by immuno-
histochemistry staining. Representative pictures of im-
munohistochemistry staining of NEK2 are shown in
Fig. 3a-c. NEK2 immunostaining was weak or un-
detectable in adjacent noncancerous prostate tissues
(Fig. 3a). In contrast, strong staining of NEK2 was
readily seen in the cytoplasm and nucleus of PCa tis-
sues (Fig. 3b-c). A summary of NEK2 immunostaining
in PCa tissues was shown in Table 2. Apparently, the
PCa with a Gleason Score ≥8 had higher NEK2 expres-
sion than those with a Gleason Score <8. In addition,
the PCa at high pathological stages showed increased
NEK2 expression compared with PCa at low pathological
stages. Moreover, statistical analyses of the Taylor dataset
also showed that PCa with a Gleason Score ≥ 8 had higher
expression of NEK2 than those with a Gleason Score <8
(P = 0.011) at the mRNA level. In addition, overexpression
of NEK2 was also associated with metastasis, PSA failure,
and overall survival time of patient, although no
correlation between NEK2 expression at the mRNA
level and pathological stages was seen in the Taylor
dataset (Table 2).
We then use the Kaplan–Meier method to analyze the
association of NEK2 expression levels with the biochem-
ical recurrence-free time and the overall survival time of
PCa patients. The median of NEK2 expression in all PCa
tissues of the Taylor dataset was used as the cutoff to
divide all PCa tissues into high (n = 80) and low (n = 80)
NEK2 expression groups. As shown in Fig. 4, the bio-
chemical recurrence-free time of PCa patients with high
NEK2 expression levels was shorter than those with low
NEK2 expression levels. However, no correlation of the
overall survival time of PCa patients with NEK2 expres-
sion levels was seen.
Discussion
PCa affects one in nine men over the age of 65 and is
the most frequently diagnosed cancer in American males
[22, 23]. Early diagnosis through detection of serum
prostate specific antigen (PSA) and improved procedures
for surgical intervention and radiation therapy have
significantly reduced the number of fatalities [24–27].
Table 2 Association of NEK2 expression with the clinicopathological characteristics of prostate cancer
Clinical feature IRS of NEK2 in our cohort NEK2 expression in Taylor dataset
Case X  s p Case X  s p
Age(years)
<71 years 85 3.67 ± 1.43 0.904 146 7.54 ± 0.29 0.717
≥71 years 95 3.64 ± 1.70 4 7.48 ± 0.26
Serum PSA
<4 (ng/ml) - - - 24 7.58 ± 0.32 0.440
≥4 (ng/ml) - - 123 7.53 ± 0.29
Gleason score
<8 70 3.81 ± 1.08 <0.001 117 7.48 ± 0.25 0.011
≥8 28 5.36 ± 1.39 22 7.71 ± 0.37
Pathological Stage
T2 70 3.81 ± 1.08 <0.001 86 7.48 ± 0.23 0.063
T3 29 5.31 ± 1.39 55 7.58 ± 0.35
Metastasis
No 99 4.25 ± 1.35 - 122 7.47 ± 0.25 <0.001
Yes 0 - 28 7.81 ± 0.33
Overall survival
Alive - - - 131 7.51 ± 0.27 0.086
Die - - 19 7.68 ± 0.38
PSA failure
Negative - - - 104 7.46 ± 0.25 <0.001
Positive - - 36 7.66 ± 0.31
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However, there is still no effective cure for men with
advanced PCa that is often castration-resistant. Many
studies have been dedicated to identifying prognostic
markers that can be used to distinguish indolent versus
aggressive forms of PCa. NEK2 is a centrosomal locating
serine/threonine kinase required for centrosome dupli-
cation in mitosis. Expression of NEK2 is frequently up-
regulated in human cancers [9]. Recent evidence
suggests that nuclear localization of NEK2 represents a
strong predictor for drug resistance and poor prognosis
in cancer [28]. Yet, the function of NEK2 in PCa pro-
gression is still obscure. Here, we reported the expres-
sion of NEK2 was elevated in PCa both at the mRNA
and protein levels. As we just use one representative cell
line for the study, the results could not completely
reflect the relationship of NEK2 with androgen, which
need further investigation to elucidate. The expression
level of NEK2 was associated with the clinicopathological
characteristics of PCa and tumor recurrence time of PCa
patients. However, analyses of Taylor dataset revealed no
statistical difference of NEK2 expression at the mRNA
level in different pathological PCa group. Therefore, post
translational modification of NEK is likely account for the
differential expression of NEK proteins in normal prostate
and PCa cells and tissues.
Aberrant NEK2 activity has been documented in mul-
tiple malignancies, including pediatric Ewing’s sarcoma,
follicular lymphoma (FL), diffuse large B cell lymphoma
(DLBCL), mammary gland tumor, leukemia, cervical,
ovarian, breast cancers [10, 15, 16, 29–33].tumori Previous
studies have shown that NEK2 contributes to assembly
and maintenance of centrosomes and to bipolar spindle
formation [12, 34, 35]. Therefore, inappropriately high ex-
pression of NEK2 might interfere with either centrosome
integrity or chromosome segregation. However, the under-
lying cause for the increase in NEK2 expression is still un-
clear. This has led to a hypothesis that deregulation of
centrosome function could be a major contributory factor
to the genetic instability and loss of tissue differentiation
that drive most cancer progression. Similar findings from
other study indicate that aberrant expression and activity
of NEK2 drive the progression and transformation of
lymphomas that ultimately causes a more aggressive dis-
ease [31]. Specifically, overexpression of NEK2 in the
ARP-1 multiple myeloma cells causes reduced treatment
efficacy of bortezomib, doxorubicin, and etoposide [28].
Downregulation of NEK2 by shRNA inhibited myeloma
cell growth and decreased drug resistance in vitro and in
NOD-Rag/null gamma mice [19]. Paclitaxel and doxorubi-
cin in combination with Nek2 siRNA or ASO treatment
promote breast cancer cell apoptosis [36].
In summary, we reported that NEK2 was highly
expressed in PCa cells and tissues. Depletion of NEK2
inhibited proliferation and tumorigenicity of the cells.
In addition, expression of NEK2 was associated with
poor outcome of PCa patients. Thus, the expression
level of NEK2 has the potential for predicting PCa pro-
gression. A large study with more patient pool is war-
ranted to determine whether expression of NEK2 can
serve as a biomarker for PCa diagnosis and prognosis.
Conclusions
The findings demonstrate that the overexpression of
NEK2 is associated with progression in PCa and suggest
that NEK2 has the potential to serve as a biomarker for
PCa prognosis. Further validation with large sample pool
is warrant.
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Fig. 4 High NEK2 expression is linked to poor prognosis in PCa
patients. a Kaplan–Meier analyses of the biochemical recurrence-free
time of PCa patients with high NEK2 expression levels was shorter
than those with low NEK2 expression levels (P = 0.037). b The overall
survival time of PCa patients was not correlated to NEK2 expression
levels (P = 0.762)
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